From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells

Chang Gung Medical Journal

Volumn 30, Issue 1, 2007, Pages 7-16

  Wu, Mai Szu ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cyclosporine; Ion transport; Nitric oxide; Renal epithelial cells; Renin angiotensin system

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CHLORIDE CHANNEL; CYCLOOXYGENASE 2; CYCLOSPORIN A; NITRIC OXIDE; POTASSIUM CHANNEL; PROSTAGLANDIN; RAS PROTEIN; SODIUM CHANNEL;

ACUTE KIDNEY TUBULE NECROSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE COURSE; DRUG INDUCED DISEASE; GRAFT REJECTION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY EPITHELIUM; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; NEPHROTOXICITY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; CELLS, CULTURED; CYCLOSPORINE; DINOPROSTONE; EPITHELIAL CELLS; IMMUNOSUPPRESSIVE AGENTS; ION TRANSPORT; KIDNEY; KIDNEY DISEASES; MICE; NA(+)-K(+)-EXCHANGING ATPASE; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM;

EID: 34247157248     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Buurman WA, Ruers TJ, Daemen LA, van der Linden CJ, Groenewegen G. Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells. J Immunol 1986;136:4035-9.
2. Ponticelli C, Civati G, Tarantino A, Quarto di Palo F, Corbetta G, Minetti L, Vegeto A, Belli L. Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. J Am Soc Nephrol 1996;7:792-7.
3. Bach JF. Cyclosporin and autoimmune disease. Lancet 1991;338:59-60.
4. Racusen LC, Solez K. Cyclosporine nephrotoxicity. Int Rev Experi Patho 1988;30:107-57.
5. Farrell RJ. Cyclosporine-associated hypertension. Am J Med 1989;86:640-1.
6. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33:590-600.
7. Wu MS, Yu HM, Yang CW, Bens M, Huang CC, Ko YC, Vandewalle A. Cyclosporine and tacrolimus alter renin-angiotesin system in mouse medullary-thick ascending limb cultured cells. Transplantation Proceedings 2001;33:1078-9.
8. Wu MS, Bens M, Cluzeaud F, Vandewalle A. Role of F-actin in the activation of Na(+)-K(+)-Cl- cotransport by forskolin and vasopressin in mouse kidney cultured thick ascending limb cells. J Membr Biol 1994;142:323-36.
9. Wu MS, Bens M, Yu HM, Vandewalle A. Cyclosporine reduces basolateral, but not apical, nitric oxide secretion in medullary thick ascending limb cells. Transpl Int 2000;13:S321-3.
10. Wu MS, Yang CW, Bens M, Peng KC, Yu HM, Vandewalle A. Cyclosporine stimulates Na+-K+-Cl-cotransport activity in cultured mouse medullary thick ascending limb cells. Kidney Int 2000;58:1652-63.
11. Wu MS, Yang CW, Bens M, Yu HM, Huang JY, Wu CH, Huang CC, Vandewalle A. Cyclosporin inhibits nitric oxide production in medullary ascending limb cultured cells. Nephrol Dial Transplant 1998;13:2814-20.
12. Wu MS, Yang CW, Chang CT, Bens M, Vandewalle A. Cyclosporin increases the density of angiotensin LT subtype 1 (AT1) receptors in mouse medullary thick ascending limb cells. Nephrol Dial Transplant 2003;18:1458-65.
13. Wu MS, Yu HM, Bens M, Vandewalle A. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL-cotransport activity in cultured medullary thick ascending limb cells. Transplant Proc 1999;31:1180-1.
14. Wu MS, Yu HM, Bens M, Vandewalle A. Furosemide prevents the inhibitory effect of cyclosporine on intrarenal nitric oxide production. Transplant Proc 2000;32:1619-20.
15. Wu MS, Yu HM, Hong JJ, Lai BC, Huang CC, Vandewalle A. Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. Transplant Proc 1998;30:3565-6.
16. Chang CT, Hung CC, Yang CW, Vandewalle A, Wu MS. Cyclosporine decreases prostaglandin E2 production in mouse medullary thick ascending limb cultured cells. Transpl Int 2005;18:871-8.
17. Atkins RC. The changing patterns of chronic kidney disease: the need to develop strategies for prevention relevant to different regions and countries. Kidney Int Suppl 2005;S83-5.
18. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003;23: 465-76.
19. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
20. Novick AC, Hwei HH, Steinmuller D, Streem SB, Cunningham RJ, Steinhilber D, Goormastic M, Buszta C. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 1986;42:154-8.
21. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91:2144-9.
22. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, Hanson P, Mohanty PK, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693-9.
23. Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 2005;68:898-907.
24. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
25. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
26. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int 1994;46:653-65.
27. Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S. Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 1994;45:998-1005.
28. Brezis M, Heyman SN, Dinour D, Epstein FH, Rosen S. Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys. J Clin Invest 1991;88:390-5.
29. Devarajan P, Kaskel FJ, Arbeit LA, Moore LC. Cyclosporine nephrotoxicity: blood volume, sodium conservation, and renal hemodynamics. Am J Physiol 1989;256:F71-8.
30. McNally PG, Feehally J. Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol Dial Transplant 1992;7:791-804.
31. Guzman NJ, Fang MZ, Tang SS, Ingelfinger JR, Garg LC. Autocrine inhibition of Na+/K(+)-ATPase by nitric oxide in mouse proximal tubule epithelial cells. J Clin Invest 1995;95:2083-8.
32. Deppe CE, Heering PJ, Tinel H, Kinne-Saffran E, Grabensee B, Kinne RK. Effect of cyclosporine A on Na+/K(+)-ATPase, Na+/K+/2Cl- cotransporter, and H+/K(+)-ATPase in MDCK cells and two subtypes, C7 and C11. Exp Nephrol 1997;5:471-80.
33. Ferrer-Martinez A, Felipe A, Barcelo P, Casado FJ, Ballarin J, Pastor-Anglada M. Effects of cyclosporine A on Na, K-ATPase expression in the renal epithelial cell line NBL-1. Kidney Int 1996;50:1483-9.
34. Tumlin JA, Sands JM. Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A. Kidney Int 1993;43:246-51.
35. Wheatley HC, Datzman M, Williams JW, Miles DE, Hatch FE. Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 1987;43:641-7.
36. Propper DJ, Whiting PH, Mackay J, Catto GR. Glomerulotubular function in long-term renal allograft recipients. A comparison of conventional therapy with cyclosporine. Transplantation 1990;50:72-5.
37. Wang WH, White S, Geibel J, Giebisch G. A potassium channel in the apical membrane of rabbit thick ascending limb of Henle's loop. Am J Physiol 1990;258:F244-53.
38. Reeves WB, Winters CJ, Zimniak L, Andreoli TE. Properties and regulation of medullary thick limb basolateral Cl- channels. Kidney Int Suppl 1998;65:S24-8.
39. Hoffmann EK, Dunham PB. Membrane mechanisms and intracellular signalling in cell volume regulation. Int Rev Cytol 1995;161:173-262.
40. Laprade R, Noulin JF, Lapointe JY. Volume regulation and ion transport in renal cells. Curr Opin Nephrol Hypertens 1996;5:417-21.
41. O'Neill WC. Physiological significance of volume-regulatory transporters. Am J Physiol 1999;276:C995-1011.
42. Lang F, Lepple-Wienhues A, Szabo I, Siemen D, Gulbins E. Cell volume in cell proliferation and apoptotic cell death. Contrib Nephrol 1998;123:158-68.
43. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990;70:1067-116.
44. Yang CW, Ahn HJ, Kim WY, Shin MJ, Kim SK, Park JH, Kim YO, Kim YS, Kim J, Bang BK. Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney Int 2001;60:847-57.
45. Hannedouche TP, Natov S, Boitard C, Lacour B, Grunfeld JP. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. Nephrol Dial Transplant 1996;11:673-8.
46. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 1997;17:412-22.
47. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999;55:2407-14.
48. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
49. Lopez R, Llinas MT, Roig F, Salazar FJ. Role of nitric oxide and cyclooxygenase-2 in regulating the renal hemodynamic response to norepinephrine. Am J Physiol Regul Integr Comp Physiol 2003;284:R488-93. Epub 2002 Sep 19.
50. Yared A, Kon V, Ichikawa I. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. J Clin Invest 1985;75:1477-87.
51. Farman N, Pradelles P, Bonvalet JP. PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 synthesis along the rabbit nephron. Am J Physiol 1987;252:F53-9.
52. Dunn MJ. Prostaglandin 12 and the kidney. Arch Mai Coeur Vaiss 1989;82:27-31.
53. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002;61:1210-9.
54. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, Redha R, Rosivall L, Breyer MD, Bell PD. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 2003;112:76-82.
55. Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H, Okumura K. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J Hypertens 2003;21:601-9.
56. Paliege A, Mizel D, Medina C, Pasumarthy A, Huang YG, Bachmann S, Briggs JP, Schnermann JB, Yang T. Inhibition of nNOS expression in the macula densa by COX-2 derived prostaglandin E2. Am J Physiol Renal Physiol 2004;9:9.